Alerta

USE OF MIMETIC PEPTIDE CONTAINING FIBRINOGEN RGD MOTIF IN PREPARATION OF MEDICATIONS FOR PREVENTING AND/OR TREATING PARKINSON'S DISEASE

Resumen de: US20260295017A1

This disclosure belongs to the technical field of biomedicine, and discloses use of a mimetic peptide containing a fibrinogen RGD motif in preparation of medications for preventing and/or treating Parkinson's disease. A sequence of the mimetic peptide containing the fibrinogen RGD motif of this disclosure is: Gly-Arg-Gly-Asp-Ser-Pro-Leu-Ala-Pro-Ser-Cys. The applicant of this disclosure has found through research that there is abnormal accumulation of FG in substantia nigra pars compacta of PD mice, and that excessively accumulated FG in the brain may promote abnormal aggregation of α-syn in dopaminergic neurons under mediation of αvβ3 integrin receptor. The mimetic peptide provided by this disclosure can effectively inhibit the abnormal aggregation of α-syn in the dopaminergic neurons and death of the dopaminergic neurons caused by the abnormally accumulated FG in the brain, improve a motion ability of MPTP-modeled PD mice, and provide a new target and idea for PD treatment.

METHODS FOR DECREASING NEURONAL DEATH, INFLAMMATION, AND DEGENERATION

Resumen de: US20260297571A1

0000 The present disclosure provides compositions and methods for treating ALS and/or FTD and for reducing neuroinflammation and neurodegeneration, e.g., as caused by dipeptide repeat (DPR) toxicity. Particularly, the disclosure provides methods for improving neuron survival, decreasing neuroinflammation and treating ALS and/or FTD using PTPσ inhibitors.

AGENT FOR TREATING OR PREVENTING AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: US20260294875A1

An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.

Inhibitors of JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3) and Mitogen-Activated Protein Kinases (MAPK8, MAPK9, and/or MAPK10) and Methods of Using Same

Resumen de: US20260294922A1

The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3; also known as MAPK8, MAPK9, and/or MAPK10), pharmaceutical compositions thereof, and methods of using the same for the treatment, prevention, and/or amelioration of one or more diseases and/or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and/or 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting the disease and/or disorder in the subject with a suitable diagnostic method.

DUAL VECTOR SELF-INACTIVATING CRISPR/CAS9 SYSTEM

Resumen de: AU2025224578A1

A self-inactivating CRISPR/Cas9 delivery system utilizing a dual vector system may be provided. A first viral vector includes an expression unit for expression of a Cas9 nuclease and a nucleotide sequence encoding an sgRNA targeting a specific genomic locus. The second viral vector includes a nucleotide sequence encoding an sgRNA targeting expression of the Cas9 nuclease by the expression unit. The self-inactivating CRISPR/Cas9 dual vector delivery system can be used for treating a genetic gene-associated disease/disorder and/or a sporadic gene-associated disease/disorder. In embodiments, the disease and/or disorder may be a neurological disease and/or disorder. In embodiments, neurological disease and/or disorder may be Huntington's disease. Methods of treatment, medicaments, and pharmaceutical compositions may be provided.

1 H-PYRROLO2,3-BPYRIDIN-4-YL-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Resumen de: US20260297085A1

This disclosure relates to compounds of Formula (I-1) or (I-2): The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2) and are useful for the treatment of diseases or disorders, such as e.g. inflammation, autoimmune disease, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn. The disclosure further provides methods of preparing the compounds.

AROMATIC HETEROCYCLE-FUSED CYCLOHEXYL AMINOALKYL PIPERIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

Resumen de: US20260297079A1

0000 The present invention relates to an aromatic heterocycle-fused cyclohexyl aminoalkyl piperidine derivative, a preparation method and use thereof. Specifically, the present invention provides a compound of general formula (I), a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor, use thereof for activating the activities of a 5-HT<1A >receptor and dopamine D<2 >and D<3 >receptors, and use thereof in the preparation of a medicament for Parkinson's disease. 0000

USES OF REGULATORY T CELLS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: AU2025239644A1

Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.

ANTI-TAU ANTIBODIES

Resumen de: AU2025239656A1

The present disclosure provides anti-tau antibodies, including compositions and methods of using such antibodies for treating Alzheimer's disease.

METHODS OF TREATING OXIDIZED PHOSPHATIDYLCHOLINE-ASSOCIATED DISEASES

Resumen de: US20260297217A1

0000 Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.

2-AZASPIRO3.4OCTANE DERIVATIVES AS M4 AGONISTS

Resumen de: EP4813390A2

Provided herein are compounds according to Formula (I)or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁵, and R⁷ are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

IMIDAZO 1,2-B PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF

Resumen de: EP4813991A1

Provided are a novel compound, a use thereof for inhibiting the activity of CDK12 and/or CDK13 and degrading cyclin K, a pharmaceutical composition comprising the same, and a use thereof for the treatment of diseases associated with CDK12 and/or CDK13 and/or cyclin K, such as cancer. According to the present invention, the compounds exhibit excellent inhibitory activity and selectivity against CDK12 and/or CDK13, and induce degradation of cyclin K, and thus can be useful for the treatment of cancers such as breast cancer or gastric cancer.

PREPARATION OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR, AND USE THEREOF

Resumen de: EP4813985A1

Provided are a compound represented by formula I, a stereoisomer, a deuterated substance, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as the use thereof as a BRAF regulator in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description.

AUTOPHAGY ENHANCERS

Resumen de: AU2025235730A1

The present disclosure is generally directed to tetracyclic analogs that modulate autophagy in a subject suffering from alpha-1 antitrypsin deficiency (ATD) and possibly other autophagy associated diseases or disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

Use of CFTR Modulators For Treating Cerebrovascular Conditions

Resumen de: US20260284023A1

Methods of use of CFTR corrector compounds, particularly lumacaftor and tezacaftor, to treat reduced cerebral perfusion associated with heart failure, sudden sensoneurinal hearing loss, vascular dementia, arterial hypertension, ischemic stroke, hemorrhagic stroke, heart disease, diabetes and Alzheimer's disease by treatment with an amount sufficient to provide a proteostatic effect on cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in cerebral artery smooth muscle cells and an increase in cerebrovascular perfusion in the patient.

COMPOSITION FOR USE IN PREVENTING, TREATING OR AMELIORATING AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: WO2026197766A1

The present invention relates to a composition comprising a compound represented by chemical formula 1 for use in preventing, treating, or ameliorating amyotrophic lateral sclerosis (ALS), and a use thereof. The composition of the present invention can exhibit an excellent effect in preventing, treating, or ameliorating amyotrophic lateral sclerosis (ALS) and/or related symptoms.

PHARMACEUTICAL COMPOSITION FOR PREVENTING/TREATING ALZHEIMER'S DISEASE

Resumen de: WO2026193686A1

The present invention belongs to the technical field of biopharmaceutics, and specifically relates to a pharmaceutical composition for preventing and/or treating Alzheimer's disease. Provided in the present invention is an NPAFP protein-based pharmaceutical composition. The composition exhibits significant effects in anti-oxidation, improving mitochondrial quality, reducing the secretion of Aβ42, ameliorating the pathological state caused by Tau PFF, etc., thereby providing a new idea for the prevention and treatment of Alzheimer's disease.

CRISPR SCREENING FOR LIPID DROPLET REGULATION IN BRAIN CELLS

Resumen de: WO2026198539A1

The present disclosure provides products and methods for modulating brain lipid function and dysfunction in a subject. In some aspects the methods are useful for slowing the progression of or preventing the development of Alzheimer's Disease or for treating Alzheimer's disease. The disclosure provides the results of a genome-wide CRISPR screening to reveal regulators of oligodendrocyte lipid dysfunction.

Verfahren zur Herstellung dopaminerger neuronaler Organoide (d-NOs) und deren Verwendung zur Behandlung der Parkinson-Krankheit

Resumen de: DE102025111075A1

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von dopaminergen neuronalen Organoiden (d-NOs) mit Nachweis der Dopaminfreisetzung in biologisch wirksamen Konzentrationen. Darüber hinaus umfassen d-NOs neben dopaminergen Neuronen auch funktionell miteinander verbundene GABAerge, glutamaterge und cholinerge Neuronen sowie Gliazellen, wodurch sie zu einem multizellulären Organoid mit einer für das Mittelhirn repräsentativen Zellzusammensetzung und Funktion werden. Daher zeigen die d-NOs der Erfindung eine komplexe Regulation dopaminerger Neuronen durch verwandte exzitatorische und inhibitorische Neuronen, was auf Kontrollmechanismen hindeutet, die beispielsweise eine Überproduktion und Freisetzung von Dopamin verhindern können. Die Erfindung bezieht sich auch auf die n-NOs als Implantat oder zur Verwendung bei der Behandlung der Parkinson-Krankheit. Darüber hinaus bezieht sich die Erfindung auf die Verwendung der d-NOs für Wirkstoffscreenings.

COMPOSITION COMPRISING GV1001 FOR PREVENTING OR TREATING PERIODONTAL DISEASES AND DISORDERS CAUSED BY PERIODONTAL DISEASES

Resumen de: US20260284153A1

A method for treating periodontal disease, atherosclerosis caused by the periodontal disease, and/or Alzheimer's disease includes administering a composition comprising a peptide having an amino acid sequence of SEQ ID NO: 1 to a subject in need thereof. The composition is effective in suppressing osteoclastogenesis, suppressing Porphyromonas gingivalis colony formation, and suppressing gingipain expression. Further, the composition is safe to a living body and involves less side effects including abnormal response.

PREVENTIVE OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE

Resumen de: US20260284041A1

0000 The purpose of the present invention is to provide a medicinal agent that exhibits the effect of inhibiting aggregation of a causative protein of an HRE-related neurodegenerative disease such as ALS. According to the present invention, rifampicin or a rifampicin compound selected from the group consisting of rifampicin, a derivative thereof, and a salt of rifampicin or the derivative and/or resveratrol or a resveratrol compound selected from the group consisting of resveratrol and a derivative thereof is an active ingredient of a preventive or therapeutic agent for a neurodegenerative disease caused by TDP-43 accumulation, or an active ingredient of a preventive or therapeutic agent for ALS.

Mivelsiran Compositions and Methods of Use Thereof

Resumen de: US20260284097A1

0000 The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as Alzheimer's disease (e.g., early onset Alzheimer's disease), using such dsRNAi agents and compositions.

METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Resumen de: US20260284230A1

0000 Provided herein are compositions and methods of treating and/or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the methods comprising administering an agent wherein the agent modifies neurons via changes in Kcnn1 protein expression or activity, which in turn modifies neuron firing and/or increases the clearance or protection from toxicity of an ALS-causing protein.

ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF

Resumen de: US20260285956A1

0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

CYCLIC COMPOUNDS USED AS MULTI-TARGET KINASE INHIBITORS AND PREPARATION METHOD THEREFOR

Nº publicación: US20260285873A1 24/09/2026

Solicitante:

SHANGHAI INST OF ORGANIC CHEMISTRY CHINESE ACADEMY OF SCIENCES [CN]
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

Resumen de: US20260285873A1

The present invention discloses cyclic compounds as multi-target kinase inhibitors and preparation methods thereof. The multi-target kinase inhibitors of the present invention are as shown in general formula I, wherein R1, R2, R3, R3a, L1, L2, L3, ring A, and ring B are as shown in the Specification and Claims. The present invention also discloses preparation methods of general formula I and its inhibitory activity against multiple kinases. The compounds of general formula I described in the present invention can be used for treating cancers and neurodegenerative diseases such as Parkinson's disease, etc.